Cambridge BioMagnetics Ltd (CBM) was selected to participate in the London Technology Fund Competition 2009. Selected companies were invited to a series of workshops provided by professional experts and held over five days in July, September and October at the offices of Oracle and PricewaterhouseCoopers. Over 150 young technology companies applied and about 30 of these were selected. The programme also included an innovative corporate speed-dating event during which Dr Thanos Mitrelias, CEO and Dr Theo Trypiniotis, CSO, presented CBM’s proposition to major technology corporates and corporate venture capital funds, including BP, Shell Game Changer, Unilever Ventures, Intel Ventures, Eli Lilly and GSK. The event was held on 16 September at the Chartered Accountants' Hall in the City of London. After the speed-dating event, CBM was shortlisted as a semi-finalist and Drs Mitrelias and Trypiniotis presented CBM’s business plan to a panel of judges at Oracle's offices in the City of London on 30 September.

Dr. Thanos Mitrelias, CEO of CBM, said "We were very excited to be selected to participate in the LTF competition and the outcome exceeded all our expectations - the structure of the workshops and the material they covered were of high quality and very well thought through. It is not an exaggeration to state that it was a brilliant and extremely comprehensive course on how to successfully build a start-up technology company. I have been involved in the entrepreneurial scene for more than 10 years, and have found that the LTF competition towers above most of the activities/events I participated in before. Furthermore, the speed-dating event was a truly unique experience and we are already exploiting useful opportunities which came out of the meetings".

David M’Meekin, chairman of the London Technology Fund, said, "The brief encounters are designed to help overcome the barriers innovative technology entrepreneurs face in trying to understand what really matters to major potential customers, suppliers and trade investors. The global corporates also have the chance to see some of the most exciting technology developments coming out of London. The event provided a forum for these parties to talk to each other and we are delighted at the high level of interest it generated".
Further information about the London Technology Fund Competition can be found at:

A related article was also published in the Independent on 10 Nov. 2009. A copy can be found at:

About Cambridge BioMagnetics

Cambridge Biomagnetics (CBM) is a spin-off from the University of Cambridge and has developed a disruptive microtagging technology for routine marking of vast numbers of biochemicals. The patented platform technology is based on microtags having unique magnetic ‘bar codes’. The key benefit is multiplexing, i.e. tagging and analysing many compounds in a single test. By dispersing the tags in batches of goods (e.g. chemicals or fuel) and by subsequently extracting and decoding the tags, these are effectively marked for tracing and authentication. Vast numbers of codes uniquely mark vast numbers of goods. The microtagging technology will also be used for rapid and reliable screening of biological samples in a highly multiplexed manner for clinical diagnostics. The microtags will encode large numbers of biomarkers, which are specific probes for a wide variety of clinical tests. CBM develops microtags as well as low-cost, highly portable analysis systems to decode them, especially for applications on site.

For more information contact:

Dr Thanos Mitrelias
President and CEO, Founder
thanos.mitrelias@cambridge-biomagnetics.com

Dr Theo Trypiniotis
CSO, Founder
theo@cambridge-biomagnetics.com

Cambridge Biomagnetics Ltd
St John's Innovation Centre
Cowley Road
Cambridge CB4 0WS
www.cambridge-biomagnetics.com